Jinghua Pharmaceutical Group (002349.SZ): Sun Company's Ningxia Senxuan resumes production

On July 19th, Gelonhui learned that Jinghua Pharmaceutical Group (002349.SZ) received a notice of resumption of production from its subsidiary Ningxia Senxuan Pharmaceutical Co., Ltd. (hereinafter referred to as 'Ningxia Senxuan') on July 19th, 2024. Ningxia Senxuan has completed its rectification and self-organized expert acceptance, and has passed the on-site verification of the stopping and rectification situation by experts organized by various competent authorities. Ningxia Senxuan has now resumed work and production in an orderly manner. During the suspension period, Ningxia Senxuan actively cooperated with the relevant competent authorities' investigation and strictly complied with national laws, regulations, rules and standards for ecological environment protection under the supervision and guidance of relevant departments.

Gelonghui FinanceJul 19 04:48 ET

Jinghua Pharmaceutical Group (002349.SZ): Currently, the company's product Jidesheng Snake Drug Tablet does not have a direct export business.

Jinghua Pharmaceutical Group (002349.SZ) stated on the investor interaction platform on July 15 that there is currently no direct export business for the company's product, Jidesheng Snake Tablet.

Gelonghui FinanceJul 15 04:48 ET

Jinghua Pharmaceutical to Build Medicine Production Base for 1 Billion Yuan

Jinghua Pharmaceutical Group (SHE:002349) plans to construct a medicine production base for 1 billion yuan, the company said in its filing on the Shenzhen Stock Exchange. The production base will be l

MT NewswiresJun 12 02:44 ET

Jinghua Pharmaceutical Group (002349.SZ) intends to invest about 1 billion yuan to build a modern production base for Chinese patent medicines and chemical preparations.

On June 11, Gelunhui reported that Jinghua Pharmaceutical Group (002349.SZ) announced that the company plans to build a modern production base for Chinese patent medicine and chemical preparations according to its own development needs. Recently, it signed a "Cooperation Framework Agreement for the Construction of the Modern Production Base of Jinghua Pharmaceutical Group" with the Management Committee of Shanghai Shibei Hi-Tech Industrial Development Zone, Nantong City, Jiangsu Province. The company plans to build a modern production base for Chinese patent medicine and chemical preparations. The project will be located in an area of about 160 mu in Changtai Road West and Xinning Road South, and Changtai Road West and Xinning Road North in Chongchuan District, Nantong City. The plot ratio of the project is greater than 1.6, and the planned construction area is about 180,000 square meters. The land is of

Gelonghui FinanceJun 11 04:49 ET

Jinghua Pharmaceutical Group Co., Ltd. (SZSE:002349) Looks Interesting, And It's About To Pay A Dividend

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Jinghua Pharmaceutical Group Co., Ltd. (SZSE:002349) is abou

Simply Wall StJun 7 20:27 ET

jinghua pharmaceutical group (002349.SZ) 2023 equity distribution: 0.92 yuan per 10 shares.

Jinghua Pharmaceutical Group (002349.SZ) announced that its annual equity distribution plan for 2023 is as follows: based on the company's current...

Zhitong FinanceJun 3 05:07 ET